Last reviewed · How we verify
Rifampin Oral Capsules
At a glance
| Generic name | Rifampin Oral Capsules |
|---|---|
| Also known as | RIFADIN™, GW679769 (Casopitant) oral tablets |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (PHASE4)
- Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects (PHASE1)
- A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets (PHASE1)
- A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifampin Oral Capsules CI brief — competitive landscape report
- Rifampin Oral Capsules updates RSS · CI watch RSS
- Amgen portfolio CI